This page shows the latest CAR therapies news and features for those working in and with pharma, biotech and healthcare.
Abecma is a CAR T cell therapy approved for pre-treated myeloma patients. ... Samit Hirawat, chief medical officer, BMS said: “CAR T cell therapies have shown transformational potential for the treatment of haematologic malignancies and we, with our
BMS) and monetisation for ex-US milestones and royalties from CAR T cell therapies ide-cel and bb21217.
Breyanzi joins other approved CAR T therapies on the market from Gilead/Kite and Novartis. ... BMS, Novartis and Gilead/Kite’s respective CAR T therapies all carry a black box warning for neurotoxicity, as well as cytokine release syndrome – an
In oncology, CAR-T therapies involve such complex approaches that they can hardly just be called drugs anymore. ... We may still be calling companies ‘pharma’ when their gene therapies hardly count as pharmaceuticals.
Selecting the right target is fundamental for the successful development of first-in-class cell therapies. ... In 2017, Gilead paid $11.9bn to acquire Kite and its pipeline of chimeric antigen receptor T cell (CAR-T) therapies.
BMS also agreed similar conditional payments, dependent on approval, for Celgene’s multiple sclerosis therapy Zeposia (ozanimod) and another CAR-T therapy, ide-cel (idecabtagene vicleucel). ... therapies. The CAR-T therapy targets CD19, a protein which
More from news
Approximately 1 fully matching, plus 92 partially matching documents found.
Historically, both large pharmaceutical and small biotechnology companies have relied on both internal and external sourcing of innovative and promising therapies. ... and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers
impact on the initiation and completion of hundreds of clinical trials involving investigational therapies for many serious diseases. ... Therapy mechanism of action – immunosuppressive therapies and therapies that require complex and prolonged
Thanks to the CAR construct, the engineered T cells can recognise and attack the CD19-expressing cancer cells. ... This composition could confer efficacy and safety advantages, including fewer adverse effects such as cytokine release syndrome (CRS) and
At the spear point is China’s emergence as the epicentre of biotech research and development, with its performance on CAR-T therapies turning heads. ... We are introducing the international best practices of developing CAR T to our China team and
year. The promise of the molecule is great, with analysts seeing it as a possible challenge to Novartis and Gilead’s CAR-T therapies. ... This means its clinical outcomes could match those seen in the CAR-Ts, but without the complexity and cost of
More from intelligence
Approximately 0 fully matching, plus 28 partially matching documents found.
It is also charged with developing HCP engagement on gene silencing technology and educating on cell therapies such as CAR-T, and the new business unit will provide core expertise in ... He says this will be needed to ensure advanced therapies realise
Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
For example, all CAR-T cell therapies were paused as intensive care unit beds were needed to help COVID-19 patients recover. ... New therapies that minimize hospital visits may have to be prioritized by pharmaceuticals and MedTech companies.
Instead, we carried out in-depth interviews with different types of stakeholders who had considerable experience working on early CAR-T therapies and clinical trials. ... Both of these scenarios were true in the case of the CAR-T treatment.
It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach. ... This approach can make targeted therapies like CAR-T a reality. A good example at GOSH is in bone marrow transplants.
However, CAR T-cell therapies stop working in some patients and severe toxicity can also occur. ... Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).
Recently these have included advanced genetic therapies, such as viral mediated gene transfer and CAR-T therapies.
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...